Inflammatory bowel disease (IBD) is a chronic, relapsing disease that severely affects patients’ quality of life. The exact cause of IBD is uncertain, but current studies suggest that abnormal activation of the immune system, genetic susceptibility, and altered intestinal flora due to mucosal barrier defects may play an essential role in the pathogenesis of IBD. Unfortunately, IBD is currently difficult to be wholly cured. Thus, more treatment options are needed for different patients. Stem cell therapy, mainly including hematopoietic stem cell therapy and mesenchymal stem cell therapy, has shown the potential to improve the clinical disease activity of patients when conventional treatments are not effective. Stem cell therapy, an emerging therapy for IBD, can alleviate mucosal inflammation through mechanisms such as immunomodulation and colonization repair. Clinical studies have confirmed the effectiveness of stem cell transplantation in refractory IBD and the ability to maintain long-term remission in some patients. However, stem cell therapy is still in the research stage, and its safety and long-term efficacy remain to be further evaluated. This article reviews the upcoming stem cell transplantation methods for clinical application and the results of ongoing clinical trials to provide ideas for the clinical use of stem cell transplantation as a potential treatment for IBD.
Microbial diseases represent a significant challenge to global health, highlighting the importance of developing novel alternative antibacterial agents. The widely used spice and traditional medicinal plant Zingiber officinale and its derivatives have been demonstrated to possess promising antibacterial properties. The aim of the present study was to assess the antibacterial efficacy of Zingiber officinale-derived exosome-like nanoparticles (ZODENs) against a model bacterium, Escherichia coli (E. coli). The ZODENs were isolated from the rhizome of Zingiber officinale and subjected to morphological, size distribution, and zeta potential characterization. The bacterial growth curve assays and colony formation assays demonstrated that the E. coli bacterial growth was remarkably inhibited following incubation with ZODENs. The ZODENs were observed to be internalized by the E. coli bacteria following incubation, and subsequently demonstrated remarkable bacterial killing effects. Furthermore, the ZODEN-derived lipids, rather than the remaining fractions, demonstrated the capacity to inhibit bacterial cells, indicating that the antibacterial activity of ZODENs was at least partially attributable to its lipid content. These findings have paved the way for the development of ZODEN-based novel antibacterial agents and will facilitate the future clinical translation of plant-derived nanomedicines.